Isotechnika Inc. Announces Two Patents Regarding its Diabetes Test
Monday October 28, 6:30 am ET
Trades on Toronto Stock Exchange - (TSX:ISA)
EDMONTON, Oct. 28 /CNW/ - Isotechnika Inc. (TSX:ISA - News) announces today that its wholly owned diagnostics division, Isodiagnostika has received from the United States Patent and Trademark Office, two patents relating to its novel diagnostic test, Diatest.
ADVERTISEMENT
Patent number 6,461,870 relates to a C13 Glucose breath test for the diagnosis of diabetic conditions and monitoring glycemic control. Patent number 6,468,802 relates to the test kit necessary to perform the test.
"This test is a novel diagnostic for determining not only diabetes but insulin resistance. Monitoring insulin resistance levels is important as a precursor to diabetes. Such a test will provide physicians with a valuable tool in determining not only if a patient is diabetic, but whether that patient may be predisposed to diabetes. Based upon the physicians' assessment, lifestyle changes and medication may be prescribed to prevent the advancement of the diabetic state." states Dr. Robert Foster, Chairman and CEO. "We are looking at various options regarding the marketing of this test," states Joseph Koziak, Executive Vice President. "We can market Diatest on our own, but we are also exploring potential licensing and distribution options as well. We are very excited about the possibilities."
This press release contains forward looking statements. Forward looking statements, including the Company's belief as to the potential of Diatest, the Company's expectations regarding the issuance of additional patents and the benefits provided by current and prospective patents, and the Company's ability to protect its intellectual property, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of Diatest, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize Diatest, the development of alternative products by the Company's competitors, the inability of the Company to defend its patents from infringement by third parties, the risk that the Company's patents may be subsequently shown to be invalid, infringe the patents of others, uncertainties related to the research and development of diagnostics, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian commissions and the Toronto Stock Exchange for additional information on risks and uncertainties relating to the forward looking statements. Investors are cautioned against placing undue reliance on forward looking statements. The Company does not undertake to update these forward looking statements.
About Isotechnika Inc.
Isotechnika Inc. is an international life sciences company headquartered in Edmonton, Alberta with additional operations in Arizona. Isotechnika Inc. and Roche have signed an agreement for the global co-development and commercialization of Isotechnika's innovative transplant drug, ISA247. This agreement represents the largest Canadian drug development deal between a large pharma and a biotech company. Isotechnika Inc. is an international life sciences company headquartered in Edmonton, Alberta with additional operations in Arizona. The company is focused on the development of immunosuppressive therapeutic drugs for use in organ transplant patients and in the treatment of autoimmune diseases. Its founders and scientific team have developed a novel, multi-platform drug, ISA247, which has progressed through discovery, pre-clinical and Phase 1 human clinical trials in less than five years. ISA247 is currently undergoing Phase 2 human clinical trials in renal transplantation and psoriasis, an established market for drugs of this class is in excess of 2.2 billion USD per year globally. Isotechnika Inc. is an S&P/TSX Composite Index company publicly traded under the symbol ISA. More information on Isotechnika can be found at www.isotechnika.com.
For further information
Joseph Koziak, Executive Vice President, Isotechnika Inc., (480) 505-0543, (480) 505-0540 (fax), jkoziak@isotechnika.com
Gordon Agopsowicz, Director, Investor Relations, Isotechnika Inc., (780) 487-1600 Ext. 245, (780) 484-4105 (fax), gagopsowicz@isotechnika.com
Archived images on this organization are available through CNW E-Pix at newswire.ca. Images are free to members of The Canadian Press. |
